Navigation Links
MiStent SES demuestra ser único en el entorno clínico
Date:10/28/2013

da con pruebas de la función endotelial realizadas en dos ensayos demostraron la cicatrización de tipo de stent de metal desnudo con mantenimiento de la función endotelial normal.

El doctor Ormiston comentó: "MiStent es el único producto en su clase en optimizar las propiedades de suministro de fármaco local ofreciendo hasta nueve meses de presencia de farmaco con solo tres meses de absorción de polímero. Dado que el fármaco persiste tres veces más que el polímero, MiStent elimina el efecto inflamatorio del polímero rápidamente y retiene el fármaco antiinflamatorio y antirrestenótico seis meses más allá de la presencia del polímero".

Dennis Donohoe, M.D., asesor médico de Micell, añadió: "Estamos encantados con los hallazgos clínicos de dos años en DESSOLVE I y II y específicamente con respecto al hallazgo único de una falta de progresión de pérdida de lumen tardía en un período de 18 meses, en combinación con una excelente cicatrización de tejido como se muestra mediante la imagen clínica detallada".

Los datos incluidos en el TCT se incluyeron recientemente en un documento revisado por homólogos publicado por JACC Cardiovascular Interventions: "First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus–Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)". Los autores de este documento incluyeron los investigadores jefe del ensayo DESSOLVE I, William Wijns, M.D., Ph.D., del Cardiovascular Center, Aalst, Bélgica, y John Ormiston, M.B.Ch.B., de la Mercy Angiography Unit, Auckland, Nueva Zelanda.

Acerca de MiS
'/>"/>

SOURCE Micell Technologies
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. MiStent SES erweist sich im klinischen Umfeld als einzigartig
2. MiStent SES Shown to be Unique in Clinical Setting
3. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
4. Micell Technologies Receives CE Mark Approval for MiStent SES
5. Blue Belt Technologies annonce que le Golden Jubilee National Hospital a réalisé la première opération NavioPFS darthroplastie unicondylaire du genou
6. Blue Belt Technologies Announces Golden Jubilee National Hospital Completes Initial NavioPFS Unicondylar Knee Replacement Surgery
7. Blue Belt Technologies kondigt eerste operatie in het Verenigd Koninkrijk aan die wordt uitgevoerd met het NavioPFS-systeem: een unicondylaire knievervanging
8. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
9. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
10. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
11. Se prepara para entrar en ensayos clínicos una nueva inmunoterapia contra el cáncer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: ... congratulations to the four winners of the International BioGENEius ... an exemplary understanding of biotechnology through science research projects. ... Challenge since its inception in the early 1990s. Sanofi ...
... Shield LLC today announced the new SILVER STORM™ waterproof, ... with other infection prevention products, at the APIC infection ... been designed to help prevent cross contamination infections which ... According to a bacteria study of common touch ...
Cached Medicine Technology:Sanofi Pasteur Commends Winners of International BioGENEius Challenge 2Sanofi Pasteur Commends Winners of International BioGENEius Challenge 3
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... , Cases of diabetes and pre-diabetes in the United States ... Johns Hopkins Bloomberg School of Public Health, with obesity apparently ... the burden of the disease has not hit all groups ... the elderly. , According to new research reported in the ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
With this more compact transducer face, this is the transducer of choice for obstetric imaging in areas with a small acoustic window....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... The OPTI LION is a compact ... single-use cassettes instead of reagents or ... patient sample is analyzed., ,In addition ... the OPTI LION measures ionized calcium ...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: